AUPH Aurinia Pharmaceuticals Inc. Stock Quote

AUPH [NASD]

Index	-	P/E	-	EPS (ttm)	-1.16	Insider Own	0.30%	Shs Outstand	141.73M	Perf Week	-11.32%
Market Cap	954.18M	Forward P/E	-	EPS next Y	-0.36	Insider Trans	2.38%	Shs Float	132.67M	Perf Month	-19.47%
Income	-156.70M	PEG	-	EPS next Q	-0.20	Inst Own	37.10%	Short Float	10.06%	Perf Quarter	-45.81%
Sales	87.90M	P/S	10.86	EPS this Y	-61.40%	Inst Trans	18.05%	Short Ratio	4.81	Perf Half Y	-34.19%
Book/sh	2.99	P/B	2.23	EPS next Y	80.30%	ROA	-33.10%	Target Price	21.31	Perf Year	-63.31%
Cash/sh	2.73	P/C	2.44	EPS next 5Y	-	ROE	-38.00%	52W Range	6.60 - 33.97	Perf YTD	-70.88%
Dividend	-	P/FCF	-	EPS past 5Y	-16.20%	ROI	-37.90%	52W High	-81.38%	Beta	0.98
Dividend %	-	Quick Ratio	12.30	Sales past 5Y	204.90%	Gross Margin	97.10%	52W Low	-4.17%	ATR	0.46
Employees	300	Current Ratio	13.10	Sales Q/Q	327.30%	Oper. Margin	-	RSI (14)	22.49	Volatility	5.82% 5.39%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	31.70%	Profit Margin	-	Rel Volume	1.99	Prev Close	6.66
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Aug 04 BMO	Payout	-	Avg Volume	2.78M	Price	6.32
Recom	1.60	SMA20	-19.10%	SMA50	-31.08%	SMA200	-52.88%	Volume	1,163,938	Change	-5.03%

May-05-22

Resumed

Cantor Fitzgerald

Overweight

$34 → $25

Dec-10-21

Upgrade

Oppenheimer

Perform → Outperform

$33 → $31

Oct-28-21

Downgrade

Oppenheimer

Outperform → Perform

$32

Jan-25-21

Reiterated

H.C. Wainwright

Buy

$30 → $35

Nov-03-20

Reiterated

H.C. Wainwright

Buy

$34 → $28

Jun-17-20

Initiated

BTIG Research

Buy

$20

May-05-20

Initiated

Cowen

Outperform

Jan-10-20

Initiated

Jefferies

Buy

$27

Dec-16-19

Reiterated

H.C. Wainwright

Buy

$25 → $32

Mar-16-18

Reiterated

Cantor Fitzgerald

Overweight

$14 → $16

Feb-08-18

Initiated

RBC Capital Mkts

Outperform

Oct-30-17

Reiterated

H.C. Wainwright

Buy

$10 → $12

May-18-17

Reiterated

H.C. Wainwright

Buy

$12 → $10

Apr-11-17

Initiated

Cantor Fitzgerald

Overweight

$14

Mar-22-17

Reiterated

FBR & Co.

Outperform

$9 → $11

Dec-30-16

Reiterated

H.C. Wainwright

Buy

$10 → $8

Aug-17-16

Reiterated

H.C. Wainwright

Buy

$7 → $10

Jun-30-16

Initiated

H.C. Wainwright

Buy

May-08-15

Initiated

MLV & Co

Buy

Sep-05-22 06:22AM	Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) market cap dropped US$71m last week; individual investors who hold 57% were hit as were institutions Simply Wall St.
Aug-08-22 11:27AM	Those who invested in Aurinia Pharmaceuticals (NASDAQ:AUPH) three years ago are up 48% Simply Wall St.
Aug-04-22 11:58AM	Why Aurinia Pharmaceuticals Stock Briefly Spiked Today Motley Fool
07:35AM	Aurinia Pharmaceuticals (AUPH) Reports Q2 Loss, Tops Revenue Estimates Zacks
06:00AM	Aurinia Reports Second Quarter and Six Months 2022 Financial and Operational Results Business Wire
Aug-01-22 04:05PM	Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Jul-27-22 12:22PM	Why Aurinia Pharmaceuticals Stock Is Sliding Today Motley Fool
Jul-26-22 02:00PM	Aurinia Pharmaceuticals Notification Regarding Inter Partes Patent Review Business Wire -16.00%
Jul-25-22 04:07PM	Aurinia Pharmaceuticals to Release Second Quarter 2022 Financial and Operational Results on August 4, 2022 Business Wire
Jul-22-22 06:05AM	Aurinia Announces Positive CHMP Opinion for LUPKYNIS® (voclosporin) for the Treatment of Adults with Active Lupus Nephritis in Europe Business Wire
Jul-15-22 04:10PM	Aurinia Pharmaceuticals Skids With Its Buyout Thesis Hanging By A Thread Investor's Business Daily -9.41%
12:01PM	Why Aurinia Pharmaceuticals Stock Is In Retreat Today Motley Fool
Jul-14-22 04:10PM	Aurinia Announces the Addition of Three Seasoned Executive Leaders to Advance Company Strategy and Performance Business Wire
Jul-05-22 03:17AM	Aurinia (AUPH) Moves 13.3% Higher: Will This Strength Last? Zacks +8.60%
Jul-01-22 04:46PM	Why Aurinia Pharmaceuticals Stock Perked Up Today Motley Fool +13.33%
Jun-06-22 04:05PM	Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire +5.01%
Jun-03-22 07:05AM	Aurinia Presents Data Demonstrating LUPKYNIS® (voclosporin) is Effective in Achieving Proteinuria Treatment Targets in Lupus Nephritis Defined by EULAR/ERA Recommendations Business Wire
May-20-22 12:07PM	Aurinia Presents Results from the Two-Year AURORA 2 Continuation Study at the 2022 European Renal Association (ERA) Congress Business Wire
May-16-22 07:17AM	Aurinia Pharmaceuticals Announces Presentations at the 2022 ERA Congress and the 2022 EULAR Congress Business Wire
May-10-22 07:15AM	Aurinia Pharmaceuticals (AUPH) Reports Q1 Loss, Tops Revenue Estimates Zacks +25.99%
06:00AM	Aurinia Reports First Quarter 2022 Financial and Operational Results Business Wire
May-06-22 04:05PM	Notice of New Dial-In Numbers for Aurinia Pharmaceuticals First Quarter 2022 Financial and Operational Results on May 10, 2022 Business Wire -6.36%
May-02-22 04:05PM	Aurinia Pharmaceuticals to Release First Quarter 2022 Financial and Operational Results on May 10, 2022 Business Wire +5.83%
04:00PM	3 Healthcare Companies With Revenue Spiking 100% or More Motley Fool
08:12AM	Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) Profit Outlook Simply Wall St.
Apr-28-22 03:02PM	Aurinia Pharmaceuticals (AUPH) May Report Negative Earnings: Know the Trend Ahead of Q1 Release Zacks
Apr-19-22 07:10AM	Aurinia Announces Year-Two Commitment to Patient Navigation Grant Program to Address Barriers for Individuals Living with Lupus and Lupus Nephritis Business Wire
Apr-04-22 04:11PM	Aurinia Pharmaceuticals Announces Presentations at the 2022 National Kidney Foundation Spring Clinical Meetings Business Wire
Mar-04-22 04:37AM	Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Analysts Are Cutting Their Estimates: Here's What You Need To Know Simply Wall St.
Mar-03-22 04:31PM	Aurinia Pharmaceuticals to Present at Upcoming Investor Conferences Business Wire -6.28%
Mar-01-22 04:49AM	While Aurinia Pharmaceuticals (NASDAQ:AUPH) shareholders have made 129% in 5 years, increasing losses might now be front of mind as stock sheds 29% this week Simply Wall St.
Feb-28-22 04:28PM	Aurinia Stock Takes a Hit, but Is It Warranted? Analyst Weighs In TipRanks -24.26%
04:03PM	Why Aurinia Pharmaceuticals Tumbled Despite Its 'Aggressive' 2022 Outlook Investor's Business Daily
09:43AM	Why Aurinia Pharmaceuticals Stock Is Crashing Today Motley Fool
07:25AM	Aurinia Pharmaceuticals (AUPH) Reports Q4 Loss, Tops Revenue Estimates Zacks
06:00AM	Aurinia Reports Fourth Quarter and Full Year 2021 Financial Results and Company Updates Business Wire
Feb-21-22 03:00PM	Analysts Estimate Aurinia Pharmaceuticals (AUPH) to Report a Decline in Earnings: What to Look Out for Zacks
Feb-10-22 04:33AM	A Subscriber Wants to Know If Aurinia Pharmaceuticals' Charts Have Improved TheStreet.com
Feb-09-22 04:17PM	Aurinia Pharmaceuticals to Release Fourth Quarter and Year End 2021 Financial Results on February 28, 2021 Business Wire
Feb-03-22 07:05AM	Aurinia Pharmaceuticals to Present at the 11th Annual Leerink Global Healthcare Conference Business Wire
Jan-26-22 01:38PM	Liontrust Investment Partners LLP Buys PayPal Holdings Inc, DocuSign Inc, Illumina Inc, Sells ... GuruFocus.com
Jan-21-22 01:38PM	Kestra Private Wealth Services, Llc Buys FT Cboe Vest Fund of Deep Buffer ETFs, iShares Core U. ... GuruFocus.com -9.82%
Jan-18-22 05:38PM	First Midwest Bank Trust Division Buys Axsome Therapeutics Inc, PROSHARES TRUST, iShares ... GuruFocus.com -5.78%
Jan-13-22 05:38PM	Pacifica Partners Inc. Buys Cenovus Energy Inc, PPG Industries Inc, Visa Inc, Sells Broadcom ... GuruFocus.com
Jan-09-22 10:30AM	My 3 Top Biopharma Stock Picks for 2022 Motley Fool
Jan-04-22 04:17PM	Aurinia Pharmaceuticals to Present at Upcoming January Investor Conferences Business Wire
Dec-24-21 11:38PM	Federated Hermes Clover Small Value Fund Buys Gray Television Inc, Verint Systems Inc, Veritex ... GuruFocus.com
05:02AM	What Type Of Shareholders Own The Most Number of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Shares? Simply Wall St.
12:38AM	Orbimed Advisors Llc Buys Adagio Therapeutics Inc, Zimmer Biomet Holdings Inc, Biogen Inc, ... GuruFocus.com
Dec-20-21 09:57AM	Implied Volatility Surging for Aurinia Pharmaceuticals (AUPH) Stock Options Zacks
Dec-18-21 12:38AM	Orbimed Advisors Llc Buys Adagio Therapeutics Inc, Zimmer Biomet Holdings Inc, Biogen Inc, ... GuruFocus.com
Dec-13-21 03:14PM	Aurinia: Long Term Prospects Are Sound, Says Oppenheimer TipRanks
Dec-09-21 09:00AM	The 2 Nasdaq Biotech Stocks to Watch Thursday Motley Fool
06:15AM	Aurinia Announces Positive Topline Results From the AURORA 2 Continuation Study of LUPKYNIS (voclosporin) for the Treatment of Adults With Active Lupus Nephritis (LN) Business Wire
Dec-07-21 10:00AM	8 Beaten-Down Pharmaceutical Stocks That Could Skyrocket In 2022 Motley Fool +5.54%
Dec-03-21 10:11AM	Aurinia (AUPH) Stock Up on Potential Acquisition Rumors Zacks -7.30%
Dec-02-21 04:10PM	Aurinia Pharma Surges Again As Novartis Joins List Of Potential Suitors Investor's Business Daily +13.27%
02:13PM	Why Aurinia Pharmaceuticals Stock Bolted Higher Today Motley Fool
12:16PM	AUPH Stock: The Novartis Takeover Talk That Has Aurinia Pharma Shares Taking Off Today InvestorPlace
Nov-22-21 04:32PM	Is An Aurinia Pharmaceuticals Buyout Coming? Why This Has Investors Doubting It Investor's Business Daily -30.98%
01:30PM	AUPH Stock: 13 Things to Know About Aurinia Pharma as Shares Crash Today InvestorPlace
11:51AM	Here's Why Aurinia Pharmaceuticals Is Falling Today Motley Fool
Nov-20-21 08:45AM	Why Aurinia Pharmaceuticals Stock Crashed in After-Hours Trading on Friday Motley Fool
Nov-19-21 08:34AM	Is the Options Market Predicting a Spike in Aurinia Pharmaceuticals (AUPH) Stock? Zacks
Nov-10-21 04:05PM	Aurinia Pharmaceuticals to Present at the 2021 Jefferies London Healthcare Conference Business Wire
Nov-09-21 12:14PM	14 Stocks to Buy According to Daniel Kims Blackcrane Capital Insider Monkey
Nov-06-21 07:03AM	Is Bristol Myers Squibb's Reported Acquisition of Aurinia a Smart Move? Motley Fool
Nov-03-21 03:31PM	Aurinia Pharmaceuticals Inc (AUPH) Q3 2021 Earnings Call Transcript Motley Fool -5.03%
10:15AM	Here's Why Bristol Myers Squibb Can't Miss Out on Aurinia Pharmaceuticals Motley Fool
07:15AM	Aurinia Pharmaceuticals (AUPH) Reports Q3 Loss, Lags Revenue Estimates Zacks
06:00AM	Aurinia Reports Third Quarter and Nine Months 2021 Financial Results and Company Updates Business Wire
Nov-01-21 10:12AM	Aurinia Announces Updated Interim Results from the AURORA 2 Continuation Study of LUPKYNIS (voclosporin) for the Treatment of Lupus Nephritis Business Wire
05:38AM	GSK denies Mail on Sunday report of interest in Aurinia Reuters
Oct-27-21 09:04AM	I Can't Confirm the Rumors on Aurinia, but I Can Confirm the Charts TheStreet.com
07:07AM	Aurinia Pharmaceuticals to Release Third Quarter 2021 Financial Results on November 3, 2021 Business Wire
Oct-26-21 04:10PM	Aurinia Pharmaceuticals to Present Five Abstracts at ASN Kidney Week 2021 and ACR Convergence 2021 Business Wire
04:47AM	Aurinia (AUPH) Surges 6.6%: Is This an Indication of Further Gains? Zacks
Oct-25-21 04:17PM	Aurinia Rockets Again On Rumored Bristol Marriage; Could Others Make A Pass? Investor's Business Daily +6.57%
07:08AM	Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH): When Will It Breakeven? Simply Wall St.
Oct-24-21 10:15AM	2 Biotech Stocks That Could Go Parabolic This Week Motley Fool
Oct-22-21 09:13PM	Why Aurinia Pharmaceuticals Stock Is Blasting Higher Today Motley Fool +26.75%
05:38PM	Bristol Myers interested in buying Aurinia Pharma - Bloomberg News Reuters
05:37PM	Rumored Bristol Myers Takeover Sends Aurinia Pharma Stock To A Record High Investor's Business Daily
04:11PM	Bristol-Myers Makes Takeover Approach to Aurinia Pharmaceuticals Bloomberg
Sep-25-21 07:00AM	2 Best Biotech Stocks to Buy Right Now Motley Fool
Sep-20-21 09:02AM	Implied Volatility Surging for Aurinia (AUPH) Stock Options Zacks
Sep-15-21 01:11PM	Aurinia Pharmaceuticals to Present at Upcoming September Investor Conferences Business Wire
10:40AM	Notable Aurinia Pharmaceuticals Insider Trades $2.92 Million In Company Stock Benzinga
Sep-10-21 01:30PM	Aurinia Pharmaceuticals to Participate in H.C. Wainwright 23rd Annual Global Investment Conference Business Wire
Aug-27-21 02:50PM	Aurinia Pharmaceuticals Shows Rising Relative Strength Investor's Business Daily
Aug-26-21 06:10AM	The five-year returns have been massive for Aurinia Pharmaceuticals (NASDAQ:AUPH) shareholders despite underlying losses increasing Simply Wall St. +9.06%
Aug-18-21 10:24AM	Aurinia (AUPH) Adds Two Candidates, Boosts Immunology Pipeline Zacks
10:00AM	Implied Volatility Surging for Aurinia Pharmaceuticals (AUPH) Stock Options Zacks
Aug-17-21 04:09PM	Aurinia Answers 'What's Next?' And Investors Punish AUPH Stock Investor's Business Daily -9.82%
06:39AM	Aurinia Adds Two Assets To Expand Its Immunology Pipeline Benzinga
06:05AM	Aurinia Acquires Novel Pipeline Assets Targeting Autoimmune and Kidney-related Diseases Business Wire
Aug-09-21 07:55AM	Aurinia Pharmaceuticals to Present at the BTIG Virtual Biotech Conference Business Wire +8.81%
Aug-07-21 04:27AM	Is Aurinia Pharmaceuticals Inc. (TSE:AUP) Popular Amongst Institutions? Simply Wall St.
Aug-06-21 01:54PM	Why Aurinia Pharmaceuticals Stock Was Surging on Friday Motley Fool +23.14%
09:30AM	Aurinia Pharmaceuticals Inc (AUPH) Q2 2021 Earnings Call Transcript Motley Fool

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MacKay-Dunn R. Hector	Director	Mar 09	Buy	11.00	5,000	54,985	11,000	Mar 11 04:05 PM
MILNE GEORGE M JR	Director	Mar 04	Buy	10.82	5,000	54,100	50,000	Mar 08 04:06 PM
Donley Matthew Maxwell	Ex VP, Intern'l Operations	Mar 02	Sale	12.01	3,052	36,655	16,224	Mar 04 04:12 PM
Martin Michael Robert	Chief Business Officer	Mar 02	Sale	12.01	4,849	58,236	59,512	Mar 04 04:13 PM
Huizinga Robert Bindert	EVP of Research	Mar 02	Sale	12.01	4,849	58,236	69,379	Mar 04 04:10 PM
Solomons Neil	Chief Medical Officer	Mar 02	Sale	12.01	4,846	58,200	90,953	Mar 04 04:10 PM
Greenleaf Peter	Chief Executive Officer	Mar 02	Sale	12.01	9,068	108,907	32,967	Mar 04 04:11 PM
Colao Massimilano	Chief Commercial Officer	Mar 02	Sale	12.01	3,205	38,492	13,495	Mar 04 04:11 PM
Miller Joseph M	Chief Financial Officer	Mar 02	Sale	12.01	3,060	36,751	6,610	Mar 04 04:12 PM
Hagan Joseph P	Director	Jan 03	Option Exercise	5.08	40,000	203,200	43,500	Jan 04 04:17 PM
Hagan Joseph P	Director	Jan 03	Sale	22.59	40,000	903,650	3,500	Jan 04 04:17 PM
Leversage Jill	Director	Dec 13	Buy	20.04	1,600	32,064	5,300	Dec 15 04:09 PM
Solomons Neil	Chief Medical Officer	Nov 11	Option Exercise	5.30	100,000	530,000	187,299	Nov 12 04:13 PM
Martin Michael Robert	Chief Business Officer	Nov 11	Option Exercise	18.38	29,000	533,020	95,861	Nov 12 04:18 PM
Martin Michael Robert	Chief Business Officer	Nov 11	Sale	29.01	40,000	1,160,280	55,861	Nov 12 04:18 PM
Solomons Neil	Chief Medical Officer	Nov 11	Sale	28.89	100,000	2,889,000	87,299	Nov 12 04:13 PM
Solomons Neil	Chief Medical Officer	Nov 10	Option Exercise	5.83	100,000	583,200	187,299	Nov 12 04:13 PM
Martin Michael Robert	Chief Business Officer	Nov 10	Sale	31.14	60,000	1,868,500	66,861	Nov 12 04:18 PM
Solomons Neil	Chief Medical Officer	Nov 10	Sale	31.11	100,000	3,110,800	87,299	Nov 12 04:13 PM
Martin Michael Robert	Chief Business Officer	Nov 09	Sale	30.17	50,000	1,508,500	126,861	Nov 12 04:18 PM
Solomons Neil	Chief Medical Officer	Nov 09	Sale	30.17	50,000	1,508,500	87,299	Nov 12 04:13 PM
Martin Michael Robert	Chief Business Officer	Nov 01	Option Exercise	3.20	45,000	144,000	221,861	Nov 03 04:20 PM
Solomons Neil	Chief Medical Officer	Nov 01	Option Exercise	5.30	45,000	238,500	182,299	Nov 03 04:24 PM
Martin Michael Robert	Chief Business Officer	Nov 01	Sale	31.64	45,000	1,423,800	176,861	Nov 03 04:20 PM
Solomons Neil	Chief Medical Officer	Nov 01	Sale	31.64	45,000	1,423,800	137,299	Nov 03 04:24 PM
Huizinga Robert Bindert	EVP of Research	Oct 25	Option Exercise	3.20	95,000	304,000	195,728	Oct 26 04:33 PM
Huizinga Robert Bindert	EVP of Research	Oct 25	Sale	29.75	130,000	3,867,500	65,728	Oct 26 04:33 PM
Martin Michael Robert	Chief Business Officer	Sep 21	Option Exercise	7.40	87,500	647,750	264,361	Sep 22 04:31 PM
Huizinga Robert Bindert	EVP of Research	Sep 21	Option Exercise	2.86	27,136	77,715	133,228	Sep 22 04:53 PM
Huizinga Robert Bindert	EVP of Research	Sep 21	Sale	23.99	32,500	779,533	100,728	Sep 22 04:53 PM
Martin Michael Robert	Chief Business Officer	Sep 21	Sale	24.02	87,500	2,101,750	176,861	Sep 22 04:31 PM
Martin Michael Robert	Chief Business Officer	Sep 20	Option Exercise	5.30	28,500	151,050	205,361	Sep 22 04:31 PM
Martin Michael Robert	Chief Business Officer	Sep 20	Sale	21.65	28,500	616,975	176,861	Sep 22 04:31 PM
Martin Michael Robert	Chief Business Officer	Sep 14	Option Exercise	4.25	90,000	382,500	266,861	Sep 14 06:16 PM
Martin Michael Robert	Chief Business Officer	Sep 14	Option Exercise	5.30	44,000	233,200	220,861	Sep 16 05:01 PM
Martin Michael Robert	Chief Business Officer	Sep 14	Sale	21.78	44,000	958,220	176,861	Sep 16 05:01 PM
Martin Michael Robert	Chief Business Officer	Sep 14	Sale	21.19	90,000	1,907,217	176,861	Sep 14 06:16 PM
Huizinga Robert Bindert	EVP of Research	Sep 14	Sale	21.75	22,500	489,375	106,092	Sep 14 05:12 PM
Martin Michael Robert	Chief Business Officer	Sep 13	Option Exercise	5.30	25,000	132,500	201,861	Sep 14 06:16 PM
Solomons Neil	Chief Medical Officer	Sep 13	Option Exercise	3.20	150,000	480,000	287,299	Sep 14 05:11 PM
Martin Michael Robert	Chief Business Officer	Sep 10	Sale	19.80	25,000	495,000	176,861	Sep 14 06:16 PM
Huizinga Robert Bindert	EVP of Research	Sep 10	Sale	19.80	10,000	197,950	128,592	Sep 14 05:12 PM
Solomons Neil	Chief Medical Officer	Sep 10	Sale	19.84	150,000	2,976,000	137,299	Sep 14 05:11 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience